Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin

1995 ◽  
Vol 102 (2) ◽  
pp. 159-172 ◽  
Author(s):  
T. Sakai ◽  
T. Matsuishi ◽  
S. Yamada ◽  
H. Komori ◽  
H. Iwashita
Keyword(s):  
Cerebrospinal Fluid ◽  
Crossover Trial ◽  
Fluid Level ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Cerebrospinal Fluid Level ◽  
Machado Joseph Disease

scholarly journals Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

2021 ◽  
pp. 100895
Author(s):  
Jens Christian Laursen ◽  
Niels Søndergaard-Heinrich ◽  
Joana Mendes Lopes de Melo ◽  
Bryan Haddock ◽  
Ida Kirstine Bull Rasmussen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Crossover Trial ◽  
Acute Effects ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection

2000 ◽  
Vol 44 (8) ◽  
pp. 2143-2148 ◽  
Author(s):  
Mark M. Huycke ◽  
M. Tarek Naguib ◽  
Mathias M. Stroemmel ◽  
Kenneth Blick ◽  
Katherine Monti ◽  
...  
Keyword(s):  
Crossover Trial ◽  
Serum Magnesium ◽  
Antiviral Agent ◽  
Chronically Ill ◽  
Normal Serum ◽  
Common Side Effect ◽  
Cytomegalovirus Disease ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Intravenous Magnesium

ABSTRACT Foscarnet (trisodium phosphonoformate hexahydrate) is an antiviral agent used to treat cytomegalovirus disease in immunocompromised patients. One common side effect is acute ionized hypocalcemia and hypomagnesemia following intravenous administration. Foscarnet-induced ionized hypomagnesemia might contribute to ionized hypocalcemia by impairing excretion of preformed parathyroid hormone (PTH) or by producing target organ resistance. Prevention of ionized hypomagnesemia following foscarnet administration could blunt the development of ionized hypocalcemia. To determine whether intravenous magnesium ameliorates the decline in ionized calcium and/or magnesium following foscarnet infusions, MgSO4 at doses of 1, 2, and 3 g was administered in a double-blind, placebo-controlled, randomized, crossover trial to 12 patients with AIDS and cytomegalovirus disease. Overall, increasing doses of MgSO4 reduced or eliminated foscarnet-induced acute ionized hypomagnesemia. Supplementation, however, had no discernible effect on foscarnet-induced ionized hypocalcemia despite significant increases in serum PTH levels. No dose-related, clinically significant adverse events were found, suggesting that intravenous supplementation with up to 3 g of MgSO4 was safe in this chronically ill population. Since parenteral MgSO4 did not alter foscarnet-induced ionized hypocalcemia or symptoms associated with foscarnet, routine intravenous supplementation for patients with normal serum magnesium levels is not recommended during treatment with foscarnet.

Sign in / Sign up

Export Citation Format

Share Document